GSC
FPRX

Ground Swell Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Ground Swell Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2K Sell
136
-60
-31% -$757 ﹤0.01% 1975
2014
Q2 		$3K Buy
+196
New +$2.81K 0.01% 1367

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ground Swell Capital's FPRX Position: Q3 2014 in Review

Ground Swell Capital reduced its Five Prime Therapeutics, Inc. (FPRX) stake by 31% in Q3 2014, selling an estimated $757 and leaving 136 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

Ground Swell Capital first reported a position in FPRX in Q2 2014 and has held it in 2 quarters since. The position peaked at $3K in Q2 2014. 63 funds tracked by Wall St. Rank hold FPRX as of Q3 2014.

  • Ground Swell Capital held 136 shares of Five Prime Therapeutics, Inc. worth $2K as of Q3 2014.
  • Ground Swell Capital sold 60 Five Prime Therapeutics, Inc. shares in Q3 2014, an estimated $757.
  • Five Prime Therapeutics, Inc. made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1975 holding.
  • Ground Swell Capital first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and has held it in 2 quarters since.
  • Ground Swell Capital's Five Prime Therapeutics, Inc. position peaked at $3K in Q2 2014.
  • 63 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.